Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose decitabine in MDS-RAEB
ChiCTR-OPC-17011122Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in myelodysplastic syndrome with excess blasts (MDS-EB), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: overall response rate. Planned start May 2017; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on ChiCTR-OPC-17011122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011122.